A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer
Ovarian Neoplasms · Fallopian Tube Neoplasms · Peritoneal Neoplasms · Neoplasm Metastasis
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 3
- Patients
- 1,630 (planned)
- Started
- Oct 22, 2025
- Main results expected
- Nov 2028
- Fully finished
- Aug 2031
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Progression-free Survival (PFS) per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 by Investigator
Measured over: Randomization to radiographic progression or death from any cause (up to 70 months)
PFS per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 by Blinded, Independent, Central Review (BICR)
Measured over: Randomization to radiographic progression or death from any cause (up to 70 months)
Changes Tremor has spotted
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT07213804 · record last updated 2026-11-04 · checked 2026-11-09 15:42 UTC